earli
detect
fibrosi
progress
develop
portal
hypertens
major
relev
prognosi
treatment
patient
chronic
liver
diseas
inde
earli
recognit
subject
prone
develop
alter
may
allow
prompt
initi
therapeut
intervent
therefor
identif
noninvas
biomark
relat
activ
fibrogen
process
major
relev
particularli
subject
sustain
liver
injuri
howev
despit
numer
attempt
uncov
molecul
object
result
elus
like
relat
natur
histori
liver
diseas
except
fulmin
hepat
failur
liver
diseas
insidi
process
clinic
detect
symptom
hepat
decompens
may
occur
week
month
mani
year
onset
injuri
heal
may
occur
without
clinic
detect
howev
particular
clinic
circumst
ie
patient
infect
hepat
c
viru
hcv
submit
liver
transplant
lt
possibl
expect
recurr
hepat
fibrosi
portal
hypertens
occur
within
short
period
time
thu
patient
constitut
popul
particularli
suitabl
identifi
noninvas
marker
earli
fibrogenesi
current
investig
took
advantag
faster
develop
hepat
fibrosi
hcvposit
lt
patient
serum
sampl
collect
shortli
lt
highthroughput
proteom
techniqu
use
ascertain
whether
proteom
pattern
sampl
differ
proteom
pattern
express
obtain
serum
sampl
noninfect
lt
patient
ultim
investig
aim
identifi
earli
circul
serum
biomark
activ
fibrogenesi
patient
liver
diseas
one
hundr
nineteen
patient
admit
liver
unit
undergo
liver
biopsi
june
januari
prospect
consid
studi
exclus
criteria
presenc
ascit
chronic
kidney
failur
hemodyalisi
moder
sever
acut
graft
reject
first
three
month
biliari
complic
antivir
treatment
first
year
lt
case
lt
recipi
addit
healthi
volunt
also
includ
studi
design
studi
two
fold
first
assess
whether
serum
proteom
profil
recurr
hcvlt
patient
differ
nonrecurr
hcvlt
patient
serum
proteom
profil
routin
liver
renal
function
test
initi
analyz
train
set
hcvrna
recurr
lt
patient
month
post
lt
show
fibrosi
stage
year
lt
pair
hepat
venou
pressur
gradient
hvpg
determin
also
avail
patient
control
group
consist
patient
without
hcvrna
recurr
underw
antivir
treatment
lt
achiev
sustain
virolog
respons
addit
serum
sampl
also
collect
nonlt
patient
advanc
liver
diseas
hcv
hepat
b
viru
hbv
present
patient
respect
wherea
etiolog
liver
diseas
viral
remain
nonalcohol
steatohepat
nash
alcohol
liver
diseas
ald
autoimmun
hepat
ah
cryptogen
thereaft
result
valid
test
set
hcv
recurr
lt
patient
serum
sampl
also
collect
month
posttransplant
proteom
profil
evalu
along
liver
renal
function
test
hvpg
measur
patient
also
perform
percutan
transjugular
liver
biopsi
hvpg
measur
perform
previous
describ
fibrosi
stage
score
use
scheuer
classif
fibrosi
minim
portal
fibrosi
periport
fibrosi
fibrosi
beyond
portal
tract
make
septum
cirrhosi
see
data
protein
profil
perform
surfaceenhanc
laser
desorptionion
timeofflight
mass
spectrometri
selditofm
use
eightspot
format
weak
cation
exchang
proteinchip
array
biorad
preliminari
studi
perform
set
experiment
condit
pool
serum
sampl
patient
without
hcvrna
recurr
patient
includ
train
set
load
onto
three
differ
type
protein
chip
array
bind
protein
revers
phase
hydrophob
interact
neg
charg
surfac
act
weak
cationexchang
immobil
metal
affin
captur
surfac
preactiv
copper
result
spectra
pool
compar
array
show
highest
number
peak
detect
highest
total
signal
intens
compar
therefor
array
use
subsequ
studi
prior
sampl
load
spot
equilibr
two
time
cm
bindingwash
buffer
sodium
acet
ph
sampl
load
duplic
randomli
order
minim
systemat
error
forti
microlit
fraction
serum
sampl
incub
cm
bind
buffer
minut
shaker
room
temperatur
afterward
array
wash
three
time
cm
wash
buffer
minut
room
temperatur
unbound
serum
protein
remov
wash
twice
deioniz
water
thereaft
array
airdri
energyabsorb
matrix
satur
sinapin
acid
aqueou
solut
contain
acetonitril
tfa
ad
twice
spot
surfac
allow
air
dri
applic
array
read
use
proteinchip
pb
ii
reader
biorad
spot
read
low
nj
medium
nj
high
nj
energi
laser
intens
masstocharg
ratio
mz
set
mz
lowenergi
laser
intens
mz
mediumenergi
laser
intens
highenergi
laser
intens
spectra
calibr
use
two
extern
calibr
standard
allinon
peptid
standard
allinon
protein
standard
biorad
peak
resolut
optim
within
mz
mz
mz
accord
low
medium
high
energi
laser
intens
respect
data
process
proteinchip
data
manag
client
softwar
biorad
minim
possibl
random
error
spectral
outlier
raw
data
normal
averag
total
ion
current
across
group
spectra
differ
twice
standard
deviat
mean
delet
furthermor
baselin
also
correct
adjust
paramet
time
expect
peak
width
peak
select
sever
paramet
select
identif
peak
cluster
thu
peak
signal
nois
equal
greater
valley
depth
superior
three
found
minimum
spectra
mz
error
lowenergi
laser
intens
spectra
medium
highenergi
laser
intens
spectra
consid
subsequ
peak
cluster
detect
verifi
manual
relabel
remov
addit
peak
perform
necessari
test
qualiti
assay
pool
normal
sera
two
individu
assess
five
protein
peak
randomli
select
cours
studi
use
calcul
coeffici
varianc
cv
describ
determin
reproduc
seldi
spectra
within
array
intraassay
interassay
respect
intraassay
spot
spot
cv
peak
intens
mass
accuraci
interassay
chip
chip
cv
peak
intens
mass
accuraci
see
data
cell
obtain
american
type
cultur
collect
atcc
manassa
va
usa
immort
stabl
cell
line
repeatedli
frozen
thaw
propag
cell
seed
cellswel
vent
flask
grown
confluenc
dulbecco
modifi
eagl
medium
dmem
supplement
uml
penicillin
streptomycin
fetal
calf
serum
fc
thereaft
cell
switch
fc
incub
normox
hypox
condit
control
waterjacket
incub
forma
scientif
seri
ii
marietta
oh
treat
ngml
sigma
st
loui
mo
lipopolysaccharid
lp
ngml
sigma
aii
pm
sigma
nm
sigma
apelin
nm
phoenix
pharmaceut
burlingan
ca
fibronectin
ngml
sigma
ngml
sigma
ngml
r
system
minneapoli
mn
experi
carri
cell
line
reproduc
three
time
least
independ
assay
condit
media
harvest
concentr
use
mw
amicon
ultra
centrifug
filter
millipor
corp
presenc
fibrinogen
cchain
assess
selditofm
describ
see
data
day
liver
biopsi
ml
blood
obtain
fast
statu
serum
store
serum
albumin
aspart
aminotransferas
ast
alanin
transaminas
alt
bilirrubin
blood
urea
nitrogen
bun
measur
advia
instrument
siemen
healthcar
diagnost
tarrytown
ny
usa
aminotermin
propeptid
type
iii
procollagen
piiinp
hyaluron
acid
ha
tissu
inhibitor
matrix
metalloproteinas
measur
patient
cemark
randomaccess
autom
clinic
immunochemistri
analyz
perform
magnet
separ
enzym
immunoassay
test
advia
centaur
siemen
healthcar
diagnost
tarrytown
ny
usa
enhanc
liver
fibrosi
elf
score
calcul
use
algorithm
recommend
cemark
assay
elf
ln
ha
ln
piiinp
ln
blood
test
statist
analysi
result
perform
non
parametr
mannwhitney
u
test
kruskalw
test
dunn
post
hoc
test
appropri
quantit
data
analyz
use
graphpad
prism
graphpad
softwar
inc
san
diego
ca
obtain
written
inform
consent
patient
includ
studi
investig
approv
investig
ethic
committe
hospit
clinic
barcelona
follow
ethic
guidelin
declar
helsinki
princip
demograph
valu
patient
includ
definit
group
shown
tabl
per
select
criteria
recurr
hcv
patient
show
higher
fibrosi
elf
score
elev
hvpg
measur
greater
ast
alt
valu
non
recurr
hcv
subject
figur
depict
portion
spectra
sampl
investig
train
group
rang
dalton
mass
charg
ratio
analyz
express
pattern
spectrogram
obtain
non
recurr
hcv
patient
clearli
differ
recurr
hcv
subject
six
statist
differ
peak
identifi
figur
peptid
b
c
e
detect
shown
tabl
signal
intens
four
peak
b
c
f
markedli
higher
non
recurr
recurr
patient
wherea
invers
situat
observ
remain
two
peak
e
remark
differ
detect
analyz
peptid
mz
sinc
fulli
evid
sampl
obtain
non
recurr
hcv
patient
almost
suppress
serum
recurr
hcv
individu
intrigu
question
aris
describ
result
elucid
whether
find
result
particular
characterist
hcv
transplant
patient
rather
differenti
featur
character
earli
fibrogen
process
thu
serum
proteom
spectrum
next
analyz
healthi
individu
nonlt
fibrot
hcv
infect
patient
non
hcv
fibrot
patient
clinic
demograph
characterist
subject
shown
tabl
fibrosi
score
liver
function
test
two
group
fibrot
patient
similar
obtain
hcv
lt
patient
mass
spectrogram
individu
includ
portion
investig
shown
figur
upper
middl
lower
part
correspond
healthi
subject
fibrot
non
hcv
subject
fibrot
hcv
patient
respect
sinc
previou
experi
strike
differ
observ
peptid
subsequ
experi
focus
peak
masscharg
ratio
da
serum
sampl
analyz
healthi
subject
show
spectrogram
compat
presenc
peptid
wherea
patholog
serum
sampl
either
fibrot
non
lt
hcv
patient
fibrogen
non
hcv
subject
show
absenc
peptid
low
intens
peak
result
indic
neither
hcv
lt
account
suppress
express
peptid
serum
sampl
fibrot
patient
confirm
peptid
behav
earli
serum
biomark
fibrosi
mass
spectrometr
analysi
perform
test
group
serum
sampl
obtain
hcv
recurr
patient
month
lt
hvpg
assess
patient
averag
valu
mm
hg
serum
sampl
show
quit
similar
express
pattern
coincid
includ
differ
peptid
fragment
detect
signal
intens
fragment
data
relev
find
howev
mass
spectrum
correspond
peptid
show
low
peak
intens
sampl
obtain
hcv
recurr
patient
fact
patient
peak
intens
mz
background
level
remain
sampl
intens
rang
figur
thu
result
confirm
find
obtain
train
group
larger
group
subject
isol
protein
interest
determin
candid
protein
ident
serum
sampl
two
healthi
subject
contain
high
seldi
intens
pool
separ
tricinesdspag
figur
band
kda
excis
trypsin
analyz
lcmsm
shown
figur
two
peptid
sequenc
identifi
match
human
fibrinogen
cchain
coverag
suggest
suppress
fibrinogen
cchain
kda
fragment
earli
surrog
indic
activ
fibrogenesi
patient
liver
diseas
unveil
potenti
mechan
govern
releas
kda
peptid
ctermin
fragment
fribrinogen
chain
serum
patient
earli
fibrogen
process
cell
treat
well
known
proinflammatori
stimuli
lp
profibrogen
substanc
aii
apelin
fibronectin
hour
except
none
substanc
induc
signific
chang
express
human
fibrinogen
chain
messeng
howev
markedli
reduc
express
chain
cultur
human
hepatocyt
shown
figur
phenomenon
specif
chain
sinc
signific
chang
observ
analyz
chain
messeng
addit
cultur
media
cell
treat
display
diminish
abund
kda
fragment
fibrinogen
cchain
comparison
untreat
cell
evalu
extens
aggress
fibrogen
process
injur
liver
major
relev
diagnosi
prognosi
treatment
patient
hepat
diseas
method
current
avail
assess
liver
fibrosi
includ
serolog
determin
sever
paramet
relat
liver
function
hepat
remodel
imag
techniqu
fibroscan
arfi
use
invas
procedur
hvpg
measur
liver
biopsi
latter
still
wide
accept
gold
standard
method
assess
liver
fibrosi
specif
limit
method
extens
discuss
previous
risk
complic
low
sensit
mild
moder
fibrosi
among
remark
limit
invas
non
invas
method
respect
recent
liver
fibrosi
score
name
elf
combin
serum
concentr
substanc
relat
collagen
metabol
piiinp
tissu
remodel
ha
progress
incorpor
among
common
diagnost
tool
evalu
liver
fibrosi
howev
wherea
techniqu
found
highli
accur
patient
advanc
fibrosi
stage
appear
less
efficaci
diagnosi
mild
moder
fibrosi
stage
earli
detect
activ
fibrogen
activ
therefor
still
remain
open
challeng
liver
diseas
fibrosi
progress
evolv
long
period
time
repres
one
relev
difficulti
identifi
specif
earli
biomark
fibrosi
current
investig
issu
overcom
assess
proteom
profil
hcvposit
lt
recipi
train
set
serum
sampl
blood
sampl
obtain
month
lt
liver
biopsi
perform
year
surgeri
defin
fibrosi
stage
well
known
fibrosi
progress
acceler
recurr
hepat
c
lt
recipi
develop
fibrosiscirrhosi
within
first
year
post
transplant
therefor
rapid
fibrosi
progress
major
characterist
group
patient
reason
particularli
suitabl
uncov
serum
tag
hepat
fibrosi
selditofm
technolog
protein
chip
profil
combin
mass
spectrometri
surfac
enhanc
biochip
allow
uniform
reproduc
bind
desorpt
biomark
selditofm
also
incorpor
sampl
prefraction
markedli
decreas
complex
protein
rich
fluid
serum
allow
comparison
peak
intens
sampl
use
larg
sampl
set
current
studi
serum
protein
fraction
anion
exchang
chromatographi
base
isoelectr
point
use
ph
gradient
result
fraction
bound
weak
cation
exchang
surfac
creat
array
protein
chip
spot
surfac
select
accord
higher
accuraci
reproduc
yield
use
technolog
abl
simultan
detect
rel
protein
express
level
rang
molecular
mass
kda
although
kda
rang
appear
sensit
mean
profil
system
found
least
serum
biomark
differenti
increas
decreas
recurr
hcv
patient
among
protein
kda
protein
fulli
suppress
serum
hcv
patient
includ
train
set
contrast
readili
detect
level
protein
detect
nonrecurr
hcv
patient
assess
whether
lt
andor
hcv
infect
account
differ
express
pattern
peak
serum
sampl
nontranspl
hcv
posit
hcv
neg
subject
fibrosi
demograph
biochem
characterist
patient
fibrosi
includ
train
set
sampl
quit
similar
display
fibrot
patient
protocol
except
hepat
enzym
expect
higher
lt
recurr
hcv
patient
fibrot
nontranspl
patient
proteom
profil
hcv
posit
sampl
proteom
profil
fibrot
patient
noninfect
sera
show
low
intens
peak
kda
spectra
markedli
differ
proteom
analysi
serum
sampl
healthi
subject
includ
set
experi
display
consist
amount
protein
interestingli
differ
etiolog
nash
ald
hbv
ah
cryptogen
account
liver
fibrosi
neg
hcv
patient
emphas
close
relationship
lack
kda
protein
fibrogen
process
next
spectral
data
obtain
test
set
appli
valid
purpos
serum
sampl
includ
test
set
show
intens
mz
peak
well
valu
found
healthi
subject
non
recurr
hcv
patient
inde
sampl
peak
detect
figur
overal
result
show
markedli
decreas
express
mz
spectral
profil
sampl
patient
fibrosi
strengthen
highli
sensit
diagnost
perform
peak
major
limit
selditofm
technolog
relat
unfeas
directli
identifi
protein
interest
fact
major
protein
identif
necessari
achiev
enrich
specif
peak
chromatographi
procedur
purif
sd
gel
electrophoresi
subsequ
triptic
digest
investig
amino
acid
sequenc
trypsin
digest
kda
protein
reveal
fragment
fibrinogen
cchain
human
fibrinogen
circul
kda
glycoprotein
shown
hepat
origin
vivo
moreov
inflammatori
stimuli
may
induc
vitro
secret
glycoprotein
non
hepat
cell
includ
epitheli
cell
granulosa
cell
cervic
carcinoma
cell
trophoblast
howev
current
evid
strongli
suggest
largest
site
human
plasma
fibrinogen
hepatocyt
compris
two
symmetr
half
molecul
bound
disulphid
knot
consist
one
set
three
differ
polypeptid
term
polypeptid
encod
separ
gene
locat
chromosom
four
predomin
circul
fibrinogen
contain
aa
kda
chain
aa
kda
chain
heterogen
abund
form
consist
aa
kda
protein
show
extens
post
translat
modif
includ
phosphoryl
sulphat
glycosyl
hydroxyl
fibrinogen
cdomain
human
fibrinogen
ctermin
twothird
chain
extend
coil
oil
portion
half
dimer
fibrinogen
molecul
cfragment
releas
circul
natur
byproduct
fibrinolyt
system
activ
therefor
found
system
circul
healthi
individu
result
show
almost
suppress
express
kda
fragment
cchain
fibrinogen
patient
undergo
fibrogen
process
agreement
previous
report
nomura
f
et
al
heavi
drinker
furthermor
author
show
serum
level
fragment
recov
alcohol
intak
ceas
month
also
extend
find
hcv
infect
patient
later
fragment
describ
diagnost
valu
patient
acut
respiratori
syndrom
breast
cancer
pancreat
adenocarcinoma
regul
total
human
fibrinogen
number
proinflammatori
agent
previous
investig
use
hepatocellular
carcinoma
cell
line
vitro
model
faith
recapitul
fibrinogen
express
includ
fibrinogen
use
studi
fibrinogen
product
regul
vitro
accordingli
subsequ
assess
potenti
regulatori
role
sever
candid
mediat
express
cell
number
proinflammatoryprofibrogen
agent
previous
involv
pathogenesi
fibroprolif
process
test
among
show
signific
regulatori
activ
mrna
express
decreas
kda
fibrinogen
intens
note
howev
fold
chang
fibrinogen
induc
cell
makedli
lower
observ
sampl
fibrot
patient
mark
differ
vivo
vitro
experiment
condit
like
account
discord
instanc
human
deriv
carcinoma
cell
line
show
alter
abund
receptor
turn
could
result
sort
resist
cytokin
hand
well
known
regul
acutephas
protein
mediat
combin
cytokin
thu
rais
possibl
addit
factor
involv
inflammatori
process
also
regul
express
kda
fragment
fibrinogen
result
line
past
studi
inhibit
induct
fibrinogen
produc
decreas
synthesi
fibrinogen
hepb
cell
respect
latter
experi
also
show
parallel
diminut
mrna
level
phenomenon
seem
mediat
posttranscript
mechan
sinc
modifi
fibrinogen
gene
transcript
suggest
effect
cytokin
liver
cell
regul
level
mrna
stabil
overal
result
indic
may
regul
synthesi
postranscript
level
summari
current
investig
took
advantag
faster
develop
hepat
fibrosi
hcvposit
lt
patient
identifi
earli
circul
serum
biomark
activ
fibrogenesi
patient
liver
diseas
use
high
throughput
selditofm
technolog
unveil
differenti
protein
pattern
profil
earli
fibrosi
recurr
non
recurr
lt
patient
six
protein
peak
display
statist
signific
differ
intens
observ
within
rang
mz
peak
locat
mz
show
remark
differ
sinc
fulli
detect
nonrecurr
lt
patient
almost
suppress
recurr
lt
patient
similar
result
found
compar
sampl
healthi
subject
non
lt
fibrot
patient
hcv
posit
neg
indic
find
relat
either
lt
hcv
infect
identif
protein
peak
show
coincid
ctermin
fragment
fibrinogen
chain
moreov
cell
cultur
experi
demonstr
downregul
mrna
express
decreas
peak
intens
mz
kda
protein
cell
conclus
identifi
kda
ctermin
fragment
fibrinogen
chain
serum
biomark
earli
fibrogen
process
patient
liver
diseas
sinc
inhibit
mrna
express
cell
tempt
specul
activ
cytokin
earli
phase
liver
injuri
could
respons
impair
circul
level
fibrinogen
cchain
fragment
patient
activ
hepat
fibrogenesi
